Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

GSK and CureVac team up on COVID-19 vaccine to battle viral variants

By Brian Buntz | February 4, 2021

CureVac/GSKLate last year, GlaxoSmithKline (NYSE:GSK) and Sanofi (NYSE:SNY) announced that their joint COVID-19 vaccine was delayed.

Now, GlaxoSmithKline is hooking up with Germany-headquartered CureVac (NSDQ:CVAC) to develop a COVID-19 vaccine that can target multiple variants of the virus simultaneously. GSK plans on spending €150 million on the project, paying the first half to CureVac initially and the latter half as a milestone payment.

For GSK, the project also entails a shift in viral platform. Its previous vaccine candidate was an adjuvanted recombinant protein-based COVID-19 vaccine.

The new project, however, will use the mRNA platform that Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) have deployed in their vaccines, which were the first to win FDA authorization in the U.S.

The two companies plan to commercially launch an mRNA vaccine in 2022, pending regulatory approval.

GSK will also work with CureVac to produce up to 100 million doses of its first-generation mRNA vaccine. CureVac launched a Phase 2B/3 study to investigate the two-dose vaccine — known as CVnCoV – in late 2020.

The two companies envision that CVnCoV will be available as a general vaccine as well as a booster for recipients of early COVID-19 vaccines.


Filed Under: Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, CureVac, GlaxoSmithKline, GSK
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
GenScript
GenScript debuts single- and double-strand DNA service for cell and gene therapy development
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative
Janssen
Janssen’s company group chairman dishes on growth strategy

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50